Paracrine Stimulation of Perinatal Lung Functional and Structural Maturation by Mesenchymal Stem Cells.

Janine Obendorf  
Universitat Leipzig

Claire Fabian  
Fraunhofer-Institut fur Zelltherapie und Immunologie

Ulrich H. Thome  
Universitat Leipzig

Mandy Laube (✉ mandy.laube@medizin.uni-leipzig.de)  
Universitat Leipzig  https://orcid.org/0000-0002-7180-2858

Research

Keywords: Mesenchymal stem cells, fetal lung maturation, epithelial sodium channel, Na+ transport, preterm infants, respiratory distress

DOI: https://doi.org/10.21203/rs.3.rs-63523/v1

License: ☭  This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Mesenchymal stem cells (MSCs) were shown to harbor therapeutic potential in models of respiratory diseases, such as Bronchopulmonary Dysplasia (BPD), the most common sequel of preterm birth. In these studies cells or animals were challenged with hyperoxia or other injury-inducing agents. However, little is known about the effect of MSCs on immature fetal lungs and whether MSCs are able to improve lung maturity, which may alleviate lung developmental arrest in BPD.

**Methods:** We aimed to determine if conditioned medium (CM) of MSCs stimulates functional and structural lung maturation. As a measure of functional maturation, Na\(^+\) transport in primary fetal distal lung epithelial cells (FDLE) was studied in Ussing chambers. Na\(^+\) transporter and surfactant protein mRNA expression was determined by qRT-PCR. Structural maturation was assessed by microscopy in fetal rat lung explants.

**Results:** MSC-CM strongly increased the activity of the epithelial Na\(^+\) channel (ENaC) and the Na,K-ATPase as well as their mRNA expression. Branching and growth of fetal lung explants, and surfactant protein mRNA expression were enhanced by MSC-CM. Epithelial integrity and metabolic activity of FDLE cells were not influenced by MSC-CM. Since MSC' actions are mainly attributed to paracrine signaling, prominent lung growth factors were blocked. None of the tested growth factors (VEGF, BMP, PDGF, EGF, TGF-β, FGF, HGF) contributed to the MSC-induced increase of Na\(^+\) transport. In contrast, inhibition of PI3-K/AKT and Rac1 signaling reduced MSC-CM efficacy, suggesting an involvement of these pathways in the MSC-CM-induced Na\(^+\) transport.

**Conclusion:** The results demonstrate that MSC-CM strongly stimulated functional and structural maturation of fetal lungs. These effects were at least partially mediated by the PI3-K/AKT and Rac1 signaling pathway. Thus MSCs not only repair a deleterious tissue environment, but also target lung cellular immaturity itself.

Background

Lung maturation is a complex process that is influenced by a variety of factors. Growth factor signaling as well as ion channel functions are crucially involved in intrauterine lung proliferation and differentiation. During fetal development the lung undergoes extensive changes of fluid secretion and absorption [1]. Fluid transport across alveolar epithelial cells is mediated by Na\(^+\) influx though epithelial Na\(^+\) channels (ENaC) in the apical membrane [2]. At the basolateral side, Na\(^+\) is actively extruded by the Na,K-ATPase, generating an osmotic gradient that drives fluid diffusion across the alveolar epithelium [3]. Vectorial Na\(^+\) transport is regulated by several pathways, including steroids [4], growth factors [5, 6] and kinase signaling [7, 8]. Furthermore, surfactant is secreted by mature alveolar type II (ATII) cells to prevent alveolar collapse during end expiration [9]. Disruption of Na\(^+\) transport driven alveolar fluid clearance (AFC) and insufficient surfactant secretion due to preterm birth, can lead to serious pulmonary complications and respiratory distress.
Among them, bronchopulmonary dysplasia (BPD) is a severe neonatal chronic lung disease first described by Northway and colleagues in 1967 [10]. The so-called “old” BPD was characterized by intense inflammation, fibrosis and lung injury due to disruption of pulmonary structures [11]. In contrast, advances in neonatal care (surfactant therapy, optimized ventilation) and survival of extremely preterm infants have changed the disease pathology [12]. The “new” BPD is characterized predominantly by simplified lung structure with fewer and larger alveoli, especially in extremely preterm infants born at earlier gestational ages (24–27 weeks) [12, 13]. BPD is a multifactorial disease and a variety of therapeutic strategies have been exerted; however, current treatment options are mainly palliative and until now no promising pharmacological approach exists to prevent or cure the disease [14].

An increased interest in stem cells has emerged in recent years. Mesenchymal stem cells (MSCs) are multipotent cells found in a variety of adult tissues, such as adipose tissue, bone marrow, amniotic fluid, placenta or umbilical cord, the latter containing MSCs in the cord lining membrane as well as in Wharton’s jelly [15, 16]. The efficacy of cell-based therapies is mainly attributed to paracrine signaling [17]. MSCs secrete immunomodulatory factors and several growth factors including fibroblast growth factor (FGF), hepatocyte growth factor (HGF), epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) [18]. MSC-based studies have shown beneficial effects in animal models of BPD. Administration of bone marrow (BM)-derived MSCs and its conditioned medium for example ameliorated parenchymal and vascular injury in neonatal mice exposed to hyperoxia [19]. Furthermore, BM-derived MSCs lowered pulmonary hypertension, improved survival and preserved alveolar and vascular growth in hyperoxia-exposed rat pups [20]. MSCs also stimulated branching morphogenesis of fetal rat lung explants [21], and increased lung organoid formation and alveolar differentiation in 3D progenitor cell cultures [22]. Thus, the in vitro and in vivo studies showed promising results of MSC application, but focused mainly on repair of disease pathways by counteracting inflammation and oxygen toxicity. In contrast, few studies have investigated the effect of MSCs on lung maturation. It is yet unknown whether or not MSCs stimulate lung maturation in immature fetal lungs prior to disease onset. Since improving lung immaturity may be an effective strategy to enhance lung development and function in preterm infants, the aim of the present study was to elucidate maturational responses of fetal distal lung epithelial cells (FDLE) exposed to conditioned medium of MSCs (MSC-CM). Epithelial Na⁺ transport and structural maturation of fetal lung explants were studied as markers of maturation. Furthermore, the involved pathways of MSC’s effects were investigated by inhibiting several growth factor receptors and kinases. Our findings support the hypothesis that MSCs constitute a therapeutic option for respiratory distress in preterm infants by elevating AFC and structural lung maturation involving kinase and Rho-GTPase signaling.

**Methods**

**Cell Isolation and Culture**

**Isolation & characterization of human MSCs**
The study was approved by the ethical board of the medical faculty of Leipzig University. Umbilical cord (UC) tissue was collected after delivery from newborns whose mothers granted informed consent. MSC isolation and characterization are described in the Supplements.

Isolation of FDLE cells

All animal care and experimental procedures were approved by the institutional review board (Landesdirektion Leipzig, Permit number: T23/15). Sprague-Dawley rats were bred at the Medical Experimental Center (MEZ) of Leipzig University and housed in rooms with a controlled temperature of 22 °C, 55 % humidity and a 12 h light-dark cycle. Food and water were freely available. Rats were euthanized by Pentobarbital injection.

FDLE cells were isolated at gestational day 19 to 20 from rat fetuses as described elsewhere [23–25]. Briefly, fetal lungs were minced and digested in Hanks’ Balanced Salt Solution (Life Technologies, Carlsbad, USA), containing 0.125 % trypsin (Life Technologies), and 0.4 mg/ml DNAse (Merck, Darmstadt, Germany) for 10 min at 37 °C. Digestion was stopped with MEM (Life Technologies) supplemented with 10 % FBS. The cell suspension was centrifuged twice and the pellet resuspended in MEM. After centrifugation, cells were resuspended in MEM containing 0.1 % collagenase type I (CellSystems, Troisdorf, Germany) and 0.2 mg/ml DNAse, and incubated for 15 min at 37 °C. After adding MEM with 10 % FBS (Biochrom, Berlin, Germany), the cell suspension was centrifuged and resuspended in MEM containing 10 % FBS, and plated twice in cell culture flasks at 37 °C for 1 h to remove contaminating fibroblasts. For Ussing chamber studies, the cells were seeded on permeable Snapwell inserts with a surface area of 1.1 cm² (Costar, #3407, Corning Inc., NY, USA) at a density of 10⁶ per insert. For RNA isolation the cells were seeded on cell culture inserts with a surface area of 4.6 cm² (ThinCert, #657641, Greiner Bio-One, Frickenhausen, Germany) at a density of 2 x 10⁶ cells per insert. FDLE cells were cultured submerged in MEM with 10 % FBS, L-glutamine (2 mM, Merck), penicillin, streptomycin and amphotericin B, with daily media exchange. 24 h prior to measurements the FDLE cell medium was either replaced by MSC-CM or control medium, containing DMEM (low glucose, GlutaMAX™) with 2 % FBS, accordingly. For receptor tyrosine kinase (RTK) inhibition the respective inhibitor was added to the culture medium 24 h before analysis. The inhibitors of the VEGF receptor (Axitinib, 10 µM), the bone morphogenetic protein receptor (BMP-R; K02288, 1 µM), the platelet derived growth factor receptor (PDGF-R; AG-1296, 10 µM), the EGF receptor (EGF-R; AG-1478, 1 µM), the transforming growth factor β receptor (TGF-β-R; SB431542, 1 µM), the FGF receptor (FGF-R; FiIN-2, 1 µM), and the HGF receptor c-met (PHA665752, 1 µM) were purchased from Biomol (Hamburg, Germany). The inhibitor of the Ras-related C3 botulinum toxin substrate 1 (Rac1; Ehop-016, 1 µM) was obtained from Selleckchem (Houston, USA). The inhibitors of the phosphoinosipside 3-kinase (PI3-K; LY294002, 10 µM) and the protein kinase B (AKT; Akti 1/2, 10 µM) were purchased from Merck. Inhibitors were dissolved in DMSO and the respective controls were treated with the solvent to exclude any solvent influence on the evoked responses.
Fetal lung isolation for explant culture

Fetal rat lungs were isolated at embryonic day (ED) 15 of gestation from Sprague-Dawley fetuses according to the protocol of del Moral et al. [26]. For explant cultivation, the lungs were incubated on cell culture inserts at an air-liquid-interface for an additional four days. The culture medium was changed daily and growth was documented with a Zeiss Axio Zoom.V16 Stereo Microscope (Zeiss, Oberkochen, Germany). Every experiment was repeated at least three times with a minimum of three lungs per group. To calculate total lung explant and tissue area, microscopic pictures of whole lungs, or hematoxylin and eosin (HE)-stained whole lung slices were analyzed with Image J software (National Institutes of Health, Bethesda, USA). Image J macros used for area analysis are illustrated in the supplements. The number of peripheral airway buds was counted on the day of isolation (ED15) and two days later (ED15+2). In addition, the ratio of the increase in airway bud number from ED15 to ED15+2 was calculated, as described elsewhere [27].

Immunofluorescence staining of fetal lung explants

For immunofluorescence staining, lung explants were fixed with 4 % formaldehyde in PBS for 2 h at 4 °C. Upon fixation, frozen sections of 6 µm were cut and slides stored at -20 °C. After treatment with blocking solution (5 % BSA in 0.3 % Triton X-100/PBS) for 1 h, lung explant slices were incubated with rabbit anti-epithelial cell adhesion molecule (EpCAM) primary antibody (1:50 in blocking solution; Abcam, Cambridge, UK) at 4 °C overnight. The secondary antibody anti-rabbit (Northern Lights™ NL493 conjugated, 1:200 in blocking solution; R&D Systems, Boston, USA) was applied for 2 h. Nuclei were stained with DAPI (1 µg/ml). Immunofluorescence staining was analyzed with confocal laser-scanning microscopy (LSM710; Zeiss).

Cell permeability assay

To assess epithelial permeability, FDLE cells were cultivated on Snapwell inserts. After two days of culture, medium was changed to MSC-CM or control medium for 24 h. Afterwards the medium was replaced by phenol red-free MEM (Life Technologies) in the lower compartment and phenol red-free MEM containing FITC-dextran (0.25 mg/ml, 3-5 kDa, Merck) in the upper compartment. After incubation of cells at 37 °C for another 24 h, the medium of the lower compartment was analyzed for fluorescence intensity of FITC-dextran. A standard dilution series of FITC-dextran was used for quantification.

Ussing chamber measurements

All Ussing chamber experiments were performed four days after seeding FDLE on Snapwell inserts with an EM-CSYS-8 EasyMount Ussing chamber system (Physiological Instruments, San Diego, CA, USA) at 37 °C and continuous gas supply with 5 % CO₂ and 95 % O₂. Ussing chambers were filled with Ringer
solution containing: 145 mM Na\(^+\), 5 mM K\(^+\), 1.2 mM Ca\(^{2+}\), 1.2 mM Mg\(^{2+}\), 125 mM Cl\(^-\), 25 mM HCO\(_3\)^-; 3.3 mM H\(_2\)PO\(_4\)^- and 0.8 mM HPO\(_4\)^{2-} (pH 7.4). On the basolateral side 10 mM glucose and on the apical side 10 mM mannitol were used. Measurements with a transepithelial resistance \((R_{te})\) below 300 \(\Omega\)\(\cdot\)cm\(^2\) were excluded from analyses. Equivalent short-circuit currents \((I_{SC})\) were assessed every 20 s by measuring transepithelial potential difference \((V_{te})\) and \(R_{te}\) with a transepithelial current clamp and calculating the quotient \(I_{SC} = V_{te} / R_{te}\). After the baseline \(I_{SC}\) reached a stable plateau \((I_{base})\), amiloride (10 \(\mu\)M, # A7410, Merck) was added to the apical compartment to determine the amiloride-sensitive \(\Delta I_{SC}\) \((\Delta I_{amil})\).

To determine the maximal ENaC activity \((amil_{max})\) 140 mM of basolateral Na\(^+\) was replaced by 116 mM N-methyl-D-glucamine (NMDG\(^+\), # M-2004, Sigma-Aldrich) and 24 mM choline, generating a 145:5 apical-to-basolateral Na\(^+\) gradient. Then the \(I_{SC}\) was measured every 5 s with a transepithelial voltage clamp. The basolateral membrane was permeabilized with amphotericin B (100 \(\mu\)M, Merck), uncoupling the Na,K-ATPase. When the maximum current increase was reached, amiloride was added to the apical compartment to determine \(amil_{max}\). On the other hand, \(ouab_{max}\) represents the maximum activity of the Na,K-ATPase. To determine \(ouab_{max}\), the apical membrane was permeabilized with amphotericin B (10 \(\mu\)M). When the \(I_{SC}\) had reached its maximum value, the Na,K-ATPase inhibitor ouabain (1 mM, Merck) was added to the basolateral compartment. The ouabain-sensitive component of the amphotericin-induced maximal \(I_{SC}\) \((ouab_{max})\) was calculated, accordingly.

**Gene expression analyses**

Total RNA was isolated five days after seeding of the FDLE cells using the PureLink™ RNA Kit (ThermoFisher) according to the manufacturers’ protocol. For elimination of genomic DNA and cDNA synthesis, the Maxima H Minus First Strand cDNA Synthesis Kit, with dsDNase (ThermoFisher) was used. Total RNA (1 \(\mu\)g) was reversely transcribed and cDNA further diluted 1:10 in Tris-EDTA (Applichem). Real time quantitative PCR (qPCR) analyses were conducted with the CFX Connect™ Real-Time PCR Detection System (BioRad, Hercules, USA) using SYBR™ Select Mastermix for CFX (ThermoFisher) and gene specific primers [4, 28]. In each qPCR run at least three biological and four technical replicates were analyzed. Serial dilutions of target-specific plasmid DNA were used for absolute quantification. Target gene expression was normalized using the reference gene mitochondrial 28S ribosomal protein S18a \((Mrps18a)\). Constant expression of \(Mrps18a\) was confirmed against other common reference genes.

**MTT**

Metabolic activity in FDLE cells was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. To this end medium was changed to culture medium containing 5 mg/ml Thiazolyl Blue Tetrazolium Bromide solution (Applichem, Darmstadt, Germany). After an incubation
period of 4 h at 37 °C, the medium was discarded and the reaction stopped with a solution containing 1:1 dimethylformamide and 20 % SDS (Roth, Karlsruhe, Germany). After 1 h incubation at 37 °C, formazan crystals were dissolved, and the supernatant analyzed at 570 nm.

**Statistical analysis**

Differences between two groups were analyzed with the unpaired t-test. Otherwise, significant differences were determined by one-way ANOVA with Tukey’s *post hoc* test. A probability of p<0.05 was considered significant for all statistical analyses. Statistical analysis was conducted using GraphPad Prism Software (version 5.03, Graph Pad software, Inc., San Diego, CA, USA).

**Results**

**UC-MSC characterization**

According to the minimal criteria defined by the International Society for Cellular Therapy, we analyzed the surface marker expression and tri-lineage differentiation capacity of isolated UC-MSCs to demonstrate their stem cell properties (Fig. S1). The cells strongly expressed the common MSC markers CD44 (94 ± 3.15 %), CD73 (94 ± 1.39 %) and CD90 (90 ± 1.88 %), whereas the expression of hematopoietic markers CD11b (26 ± 3.12 %) and CD45 (13 ± 2.24 %) was low. Analysis of adipogenic differentiation using Oil red O staining showed a high number of small intracellular lipid droplets. Staining of acidic polysaccharides with Alcian blue showed that UC-MSCs differentiated reliably into chondrogenic cells. Osteogenic differentiation was demonstrated with ALP 1 staining, although the differentiation process was slower (4 weeks) compared to chondrogenic and adipogenic differentiation (2 weeks).

**MSC-CM induces functional maturation of FDLE cells**

MSC-CM incubation of FDLE cells for 24 h significantly elevated $b_{\text{base}}$ and $\Delta I_{\text{amil}}$ 1.4-fold compared with control cells (p<0.001, Fig. 1A). MSC-CM further strongly increased $amil_{\text{max}}$ in FDLE cells compared with control cells (p<0.01, Fig. 1B). In addition, maximal Na,K-ATPase activity was strongly elevated by MSC-CM, as shown by the significantly elevated $ouab_{\text{max}}$ in FDLE monolayers (p<0.001, Fig. 1C). In conclusion, MSC-CM profoundly increased epithelial Na$^+$ transport, as well as the maximal ENaC and maximal Na,K-ATPase activity in FDLE cells.

MSC-CM-incubated FDLE cells showed a significantly higher mRNA expression of the $\alpha$-$ENaC$, $\beta$-$ENaC$ and $\gamma$-$ENaC$ subunits compared to control cells (p<0.01, p<0.001, Fig. 1D). Expression of $\alpha$-$ENaC$ was 1.6-fold higher in MSC-CM-treated cells compared to control cells. Furthermore, mRNA expression of $\beta$-$ENaC$ and $\gamma$-$ENaC$ were 1.7-fold and 1.4-fold higher in FDLE cells cultivated in MSC-CM. In addition, mRNA expression of the $Na,K$-ATPase subunits $\alpha_1$ and $\beta_1$ was significantly higher in FDLE cells grown in
MSC-CM (p<0.05, p<0.01, Fig. 1D). The \(Na,K-ATPase \alpha_1\) expression level was 1.2-fold higher, while MSC-CM elevated the \(Na,K-ATPase \beta_1\) expression 1.4-fold. These results demonstrate that MSC-CM increased mRNA expression of the involved \(Na^+\) transporters, possibly contributing to the increased \(Na^+\) transport shown before.

Another important feature of perinatal lung transition and a commonly used marker of lung maturation is the secretion of surfactant by ATII cells. Surfactant proteins A, B and C mRNA expressions were significantly induced by MSC-CM (p<0.05, p<0.001, Fig. 1E). Expression of \(Sftpa1\) was 2.1-fold higher than in control cells. Furthermore, \(Sftpb\) was 1.5-fold higher and \(Sftpc\) was 3.4-fold higher in MSC-CM-treated compared to control FDLE cells. Herein another crucial alveolar function was augmented by MSC-CM, further supporting the induction of functional maturation.

**MSC-CM enhances structural maturation of fetal lung explants**

Lung explants treated with MSC-CM for 4 days displayed an enhanced branching and structural morphology compared to control explants (Fig. 2A and E). The area of lung explants increased during culture in control and MSC-CM, but MSC-CM significantly raised explant area after 2 and 4 days in culture compared to control explants (p<0.05, p<0.001, Fig. 2A and B). To exclude that the growth surge induced by MSC-CM is the result of abnormal tissue expansion like hyperplasia, we analyzed the ratio of tissue area in relation to total lung explant area (circumference) in control and MSC-CM treated lung slices. This ratio represents a size-independent measure of tissue alterations. Notably, the ratio of tissue to total lung area was not changed, demonstrating a proportional growth induced by MSC-CM (Fig. 2C). We further calculated the increase of peripheral airway bud numbers from day 0 to day 2 in culture, which was significantly higher in MSC-CM-treated explants (p<0.05, Fig. 2D and E). To exclude possible differences in lung explant cell composition, we conducted immunofluorescence staining of EpCAM (Fig. 2F). No obvious abnormal structures were observed in MSC-CM treated lungs. Control lungs as well as lungs cultured in MSC-CM showed a comparable degree of parenchymal development, which confirms the finding that MSC-CM does not cause abnormal tissue expansion. Taken together, these results support an enhanced growth and structural maturation with regard to peripheral airway buds induced by MSC-CM, in addition to the elevated functional activity of fetal alveolar epithelial cells shown above.

**Epithelial integrity and metabolic activity are not affected by MSC-CM**

We analyzed whether epithelial barrier function is altered by MSC-CM in FDLE monolayers. Epithelial permeability was determined with FITC-dextran assays, which showed that permeability of MSC-CM-treated FDLE and control epithelia were not significantly different (Fig. 3A). The \(R_{te}\) of monolayers was equal in control medium and MSC-CM (Fig. 3B). Metabolic activity was assessed in MTT assays. MTT
assays are generally considered to determine the proliferation rate of cells, which was not affected by MSC-CM after 24 h (Fig. 3C).

**MSC-CM-induced Na⁺ transport is not mediated by growth factors**

To determine by which pathway MSC-CM increased Na⁺ transport in FDLE cells, we inhibited several growth factors by blocking their respective cellular receptor. Inhibition of the VEGF-R with Axitinib revealed that VEGF-R signaling is not involved, since MSC-CM was still able to strongly elevate $\Delta \text{I}_{\text{amil}}$ compared to control cells ($p < 0.001$, Fig. 4A). Similarly, inhibition of BMP-R with K02288 did not prevent the significant increase of $\Delta \text{I}_{\text{amil}}$ induced by MSC-CM ($p < 0.001$, Fig. 4C). AG-1296, inhibiting the PDGF-R, did also not affect the stimulation of $\Delta \text{I}_{\text{amil}}$ induced by MSC-CM ($p < 0.001$, Fig. 4C). AG-1478, which selectively blocks the EGF-R, significantly decreased $\Delta \text{I}_{\text{amil}}$ in both culture conditions; however, MSC-CM was still able to significantly increase $\Delta \text{I}_{\text{amil}}$ compared to control cells ($p < 0.001$, Fig. 4D). This indicates that EGF-R inhibition by AG-1478 was non-specific and probably mediated by a different mechanism independent of MSC-CM components. Similar observations were obtained for the following inhibitors. The TGF-β-R inhibitor SB431542 decreased $\Delta \text{I}_{\text{amil}}$ in both MSC-CM-treated and control cells ($p < 0.001$, Fig. 4E). Nevertheless, SB431542 did not prevent the increased $\Delta \text{I}_{\text{amil}}$ induced by MSC-CM ($p < 0.05$). Furthermore, inhibition of the FGF-R by FIIN-2 decreased $\Delta \text{I}_{\text{amil}}$ in both, MSC-CM-treated and control cells, and MSC-CM significantly increased $\Delta \text{I}_{\text{amil}}$ in the presence of FIIN-2 ($p < 0.05$, $p < 0.001$, Fig. 4F). In addition, PHA665752 inhibiting the HGF receptor c-Met, reduced $\Delta \text{I}_{\text{amil}}$ in MSC-CM-treated cells ($p < 0.01$, Fig. 4G), but MSC-CM significantly elevated $\Delta \text{I}_{\text{amil}}$ in the presence of PHA665752 ($p < 0.001$, Fig. 4G). Thus, none of the tested growth factor inhibitors specifically blocked the actions of MSC-CM. Therefore, the involved pathways probably did not contribute to the MSC-CM-induced stimulation of Na⁺ transport. Inhibition of the EGF-R, the TGF-β-R, the FGF-R and c-met demonstrated a general involvement in the regulation of Na⁺ transport, while VEGF-R, BMP-R and PDGF-R lacked any effect. Therefore, the stimulating effect of MSC-CM on Na⁺ transport was not affected by the inhibition of these growth factor pathways. As stated above, we report the equivalent $I_{\text{SC}}$, calculated according to Ohm’s law. In accordance to $\Delta I_{\text{amil}}$, $\Delta V_{\text{amil}}$ confirmed the lack of growth factor contribution to the stimulated Na⁺ transport by MSC-CM (Fig. S2). $R_{te}$ of the Ussing chamber measurements is also reported in the supplements (Fig. S3).

**Kinase signaling via PI3-K/AKT contributes to the MSC-mediated Na⁺ channel activity**

Inhibition of growth factor signaling via their respective receptors did not prevent the stimulating effect of MSC-CM on Na⁺ transport. Previous studies showed that PI3-K and AKT signaling increased ENaC activity [7, 29]. We therefore determined whether any of these kinases was involved in mediating the MSC-
CM effect. Incubation with MSC-CM alone strongly elevated $\Delta I_{amil}$, compared to control cells ($p<0.001$, Fig. 5A). Inhibition of AKT with Akti 1/2 significantly reduced Na$^+$ transport in both, control as well as MSC-CM-treated cells compared to cells cultured without Akti 1/2 ($p<0.001$). Notably, in the presence of Akti 1/2 MSC-CM was not able to increase Na$^+$ transport anymore, suggesting a critical involvement of AKT signaling in the stimulating effect of MSC-CM. Inhibition of AKT signaling had no effect on $R_{te}$ (Fig. 5B), while $\Delta V_{amil}$ measurements confirmed that AKT inhibition prevented the stimulating effects of MSC-CM ($p<0.001$, Fig. 5C). AKT is activated through PI3-K signaling, which is why we also determined the contribution of the PI3-K by its inhibition with LY294002. MSC-CM incubation significantly enhanced ENaC activity in FDLE cells compared to control cells ($p<0.001$, Fig. 5D). However, MSC-CM was also able to increase $\Delta I_{amil}$ in the presence of LY294002, suggesting that PI3-K signaling is not involved in the stimulating effect of MSC-CM. Indeed, there was no significant difference between MSC-CM-treated cells in the presence or absence of LY294002. However, LY294002 also strongly reduced the $R_{te}$ of MSC-CM treated FDLE cells ($p<0.001$, Fig. 5E). As we report the calculated $I_{sc}$, changes in $R_{te}$ affect the resulting equivalent $I_{sc}$. Indeed, $V_{te}$ revealed a significant reduction of $\Delta V_{amil}$ in MSC-CM-stimulated FDLE cells by LY294002 ($p<0.001$, Fig. 5F). On the other hand, $\Delta V_{amil}$ in control cells was not affected by LY294002 and importantly MSC-CM was not able to increase $\Delta V_{amil}$ in the presence of LY294002. These observations support a critical involvement of PI3-K signaling in the MSC-CM-induced Na$^+$ transport. In summary, evidence suggests that both AKT and PI3-K signaling contribute to the enhanced ENaC activity induced by MSC-CM.

**Rac1 signaling contributes to the MSC-CM-mediated ENaC activity**

Another mediator activated by RTKs is Rac1, a small Rho-GTPase, that has been shown to positively regulate ENaC activity in the kidney [30]. To analyze the involvement of Rac1 signaling, we used the Rac1 inhibitor Ehop-016 and measured the MSC-CM-induced ENaC activity. MSC-CM strongly elevated $\Delta I_{amil}$ in the absence and presence of Ehop-016 ($p<0.001$, Fig. 6A). Rac1 inhibition further significantly decreased $\Delta I_{amil}$ in MSC-CM-treated cells ($p<0.001$). Notably, $\Delta I_{amil}$ in control cells was not affected by Rac1 inhibition, suggesting that Rac1 is not required for basal Na$^+$ transport, but contributes to the stimulating effect of MSC-CM. However, Rac1 inhibition reduced the $R_{te}$ of FDLE cells cultivated in MSC-CM ($p<0.05$, Fig. 6B), which affects the calculated $I_{sc}$. Moreover, the MSC-CM-induced increase of Na$^+$ transport in the presence of Ehop-016 was not observed for $\Delta V_{amil}$ (Fig. 6C). $\Delta V_{amil}$ was strongly increased by MSC-CM and significantly reduced by addition of Ehop-016 ($p<0.001$). In contrast to $\Delta I_{amil}$, $\Delta V_{amil}$ was not different between control and MSC-CM-treated cells in the presence of Ehop-016. These results suggest that Rac1 signaling is involved in MSC-CM-stimulated ENaC activity, but is not solely responsible for the effect.

**Discussion**
MSCs are known to secrete important growth factors, and these growth factors have been shown to play a major role in lung development and epithelial integrity (Table 1). However, little is known about the effect of MSCs and their secreted factors on functional and structural lung maturation in the context of prematurity. Our results suggest that MSC-CM improves functional and structural maturation in immature fetal lungs. MSC-CM strongly stimulated Na\(^+\) transport across fetal lung epithelial cells as well as Na\(^+\) channel mRNA expression, which has not been shown before. Furthermore, growth and branching of fetal lung explants was accelerated by MSC-CM. Several studies have shown the beneficial effect of MSCs in rodent models of BPD, regardless of whether cells or CM were administered [31–33]. However, rodent models of BPD are treated with hyperoxia to induce oxygen toxicity which mimics only some pathological features of the disease [34, 35]. Moreover, newborn rodent pups are viable without O\(_2\) support and do not develop immaturity-based respiratory distress. These animal models are thus unsuitable to study the effect of MSCs on lung maturation and it remains unknown if MSCs induce maturation in immature lung cells. To our knowledge, this is the first study demonstrating a functional improvement of fetal lung cells by MSCs. This is in contrast to previous studies in which MSCs mainly counteracted the experimentally-induced damage.
| growth factor | effects on lung | cell/tissue/ organ model |
|--------------|----------------|-------------------------|
| BMP-4        | ↓ proliferation of lung endoderm; inhibited outgrowth [55] | fetal mouse lung explant |
|              | ↑ parabronchial smooth muscle cell differentiation [56] | embryonic mouse lung explant |
| EGF          | ↓ ENaC activity; Na,K-ATPase activity unchanged [57] | adult mouse collecting duct |
|              | ↑ fetal pulmonary epithelial cell growth [58] | fetal rabbit |
|              | ↓ branching in EGF-R deficient lungs [59] | neonatal mouse lung |
|              | ↑ lung growth in hypoplastic lungs [60] | fetal rabbit lung |
| FGF-10       | maintained alveolar epithelial cell proliferation [61] | neonatal mouse lung |
|              | directed bipotent progenitors towards ATII lineage [62] | neonatal rat lung |
|              | ↑ (short-term) Na,K-ATPase activity [63] | A549 cells |
|              | ↑ outgrowth of lung epithelium [55] | fetal mouse lung explant |
| HGF          | involved in septal formation [64] | mouse embryonic lung |
|              | ↓ ENaC activity [65] | nasal epithelial cells |
|              | ↑ growth and lumen formation [66] | fetal mouse alveolar epithelial cells |
|              | ↑ epithelial integrity ($R_{te}$) [67] | CFBE410 cells |
| KGF          | ↑ surfactant gene expression [68] | fetal rat alveolar epithelial cells |
|              | ↑ epithelial cell proliferation in airway and alveoli [69] | adult rat alveolar epithelial cells |
|              | ↑ AFC [42] | adult rat alveolar epithelial cells |
|              | ↑ Na,K-ATPase; ↓ ENaC mRNA expression[70] | adult rat alveolar epithelial cells |
| PDGF         | alveolar myofibroblast differentiation & alveogenesis [71] | PDGF-A mutant mice |
|              | ↑ growth of mesenchymal cells during lung development [72] | mice overexpressing PDGF-A |
|              | ↓ lung branching [73] | embryonic mouse lung |
|              | ↑ ENaC internalization [6] | mouse lung epithelial & A549 cells |
|              | ↑ alveolar epithelial to mesenchymal transition [74] | A549 cells |
| VEGF         | ↑ surfactant protein production [75] | adult rat alveolar epithelial cells |
| effects on lung                                      | cell/tissue/ organ model        |
|----------------------------------------------------|--------------------------------|
| ↑ lung angiogenesis [76]                            | neonatal rat lung              |
| ↑ growth of distal airway epithelial cells [77]     | human fetal lung explant       |
| ↑ SFTP-B positive cell number in airway epithelium [78] | fetal sheep lung              |

Na⁺ transport mediated by ENaC and Na,K-ATPase plays a central role in AFC at birth [36] and is crucial for postnatal survival, as shown by mice lacking the pore-forming α-subunit of ENaC [37]. Preterm infants with RDS had reduced airway epithelial Na⁺ transport [38] and reduced ENaC expression [39] compared with preterm infants without RDS or term infants. Furthermore, survival of adults with acute RDS (ARDS) is related to the efficiency of their AFC [40] and ARDS, i.e. as a consequence of viral infections like the novel SARS-CoV-2, is associated with high morbidity and mortality [41]. This underlines the importance of therapies that enhance AFC and lung maturation to prevent BPD or ARDS in preterm and adult patients under intensive care. Herein, we showed that FDLE cells incubated in MSC-CM display a higher ENaC and Na,K-ATPase activity as well as mRNA expression. MSCs therefore strongly stimulated functional maturation of fetal lungs in a paracrine manner. Similar effects of MSCs on Na⁺ transport were seen in models of acute lung injury (ALI) and organs rejected for transplantation. In detail, MSCs enhanced mRNA expression of Na,K-ATPase-α₁ and -β₁ subunits in a lipopolysaccharide (LPS)-induced model of ALI [42]. Furthermore, MSC-CM accelerated Na⁺ transport and epithelial integrity in a model of ALI [43]. Restored AFC was shown by MSCs and their microvesicles in lungs that were rejected for transplantation [44, 45]. These studies are in line with our results; however, they were conducted in challenged models or diseased transplants, whereas we show a stimulating effect of MSC-CM on Na⁺ transport in undamaged fetal alveolar cells. Therefore, we can infer that MSCs and their secreted factors stimulate functional maturation of fetal lung cells independent of a noxious cell environment. In addition to Na⁺ transport, secretion of surfactant by mature ATII cells is crucial for perinatal lung transition. FDLE cells cultured with MSC-CM demonstrated elevated mRNA levels of all three surfactant genes. This is consistent with findings that BM-MSCs enhance Sftpb and Sftpc in fetal ATII cells and that resident lung MSCs promote expression of Sftpc when administered in a model of ALI [46, 47].

In addition to functional maturation, we determined the structural maturation of fetal lung explants, because arrested lung development is a hallmark of BPD. We confirmed a stimulating effect of MSC-CM on growth and branching of fetal lung explants ex vivo. Similar observations have previously been shown for placenta-derived MSCs [21]. The unchanged ratio of tissue to total explant area indicates that the MSC-CM-induced growth increase is not due to abnormal cell proliferation resulting in tissue hyperplasia. MSC-CM rather led to a proportional tissue growth preserving the tissue to airspace ratio. The stimulation of growth and branching in lung explants and the increase of surfactant mRNA expression confirmed an improved structural maturation of fetal lungs.
Epithelial integrity and metabolic activity were unaltered by MSC-CM. $R_{te}$ of FDLE monolayers displayed tight monolayers of high barrier function with little dextran passage even after 24 h. Under these circumstances, MSC-CM exerted no effect on barrier function or metabolic activity. In contrast, MSC-CM stimulated the proliferation and metabolic activity of A549 cells, a human lung epithelial-like cell line [48]. The differential outcome might be due to the cells itself or the used MSC-CM. A549 cells are an immortalized cancer cell line, while we used primary fetal lung epithelial cells. Moreover, the increased proliferation in A549 cells was achieved with 50-fold concentrated MSC-CM [48], in contrast to our study where we used MSC-CM without concentration. Comparing the results obtained with lung explants to FDLE cells, 24 h MSC-CM incubation might not be long enough to induce proliferation as the growing lung explants were cultured over 4 days. The lung explants used in our study were isolated on ED15, within the pseudoglandular stage of lung development, while the FDLE cells were isolated at the late canalicular to early saccular stage. It might be explicable that proliferation (growth) was induced by MSC-CM at earlier stages of development; while functional differentiation was induced in FDLE cells, isolated from fetal pups 24–48 h prior to birth.

A variety of studies showed that MSCs secrete important factors, e.g. growth or anti-inflammatory factors. The lung mesenchyme and its secreted paracrine factors are indispensable during lung development. After determining the stimulating effect of MSC-CM, we analyzed if specific growth factors, known to play an essential role in lung development (Table 1), are involved. Inhibition of VEGF-R, BMP-R and PDGF-R did not affect Na$^+$ transport, neither in control nor in MSC-CM-treated FDLE cells. We conclude that VEGF-R, BMP-R and PDGF-R signaling are not contributing to basal as well as stimulated Na$^+$ transport. To our knowledge, no study has tested the influence of these growth factors on Na$^+$ transport and ENaC function in fetal lung epithelial cells. EGF-R, TGF-β-R, FGF-R and HGF-R (c-met) inhibition decreased MSC-CM-mediated Na$^+$ channel activity; however, Na$^+$ transport in controls was also reduced by the inhibitors. We therefore assume that the reduction of Na$^+$ channel activity likely represents a general effect, independent of MSC-CM. Additionally, Na$^+$ channel activity was still higher in MSC-CM-treated FDLE cells compared to controls in the presence of the respective inhibitor. EGF-R, TGF-β-R, FGF-R and HGF-R (c-met) signaling are thus not responsible for the stimulation of Na$^+$ transport by MSC-CM. Previous studies reported contrary results of the EGF-mediated effect on ENaC activity. Some studies showed a stimulating effect, others demonstrated inhibition of ENaC by EGF [5, 49, 50]. We observed a decrease of Na$^+$ channel activity by EGF-R inhibition that suggests EGF as a positive regulator of Na$^+$ transport in FDLE cells. However, other studies of our laboratory demonstrated that EGF reduced ENaC activity (unpublished communication), suggesting that the inhibitor might affect Na$^+$ transport independent of blocking EGF actions. Surprisingly, TGFβR inhibition lowered Na$^+$ transport in FDLE cells. TGFβ has been shown to block ENaC activity in alveolar cells and thus receptor inhibition would be assumed to enhance Na$^+$ transport [6]. On the other hand, the presence of TGFβ in MSC-CM has not been tested and the TGF-β-R inhibitor blocks not only Alk5, but also Alk-4 and Alk-7 [51], which might also affect Na$^+$ transport and possibly lead to the obtained results. Key players in lung development are FGFs, e.g. FGF-10 or KGF (FGF-7), and HGF. Inhibition of FGF-R1-4 and HGF-R (c-met) lowered ENaC activity,
suggesting that these growth factors have an impact on ENaC activity. However, neither FGF-R nor HGF-R inhibition prevented the stimulating effect of MSC-CM on Na\(^+\) channel activity. In conclusion, none of the blocked pathways was involved in the stimulating action of MSC-CM. MSCs induce Na\(^+\) transport either by a yet unrecognized signaling pathway or growth factors act in concert converging at later steps that are activated by more than one factor.

Since the growth factor analyses did not reveal cellular pathways leading to the enhanced Na\(^+\) transport, common intracellular signaling cascades were examined. These signaling cascades are activated by RTKs and stimulate Na\(^+\) transport, especially ENaC. PI3-K/AKT signaling pathway, e.g. activated through insulin or 17\(\beta\)-estradiol, was shown to stimulate ENaC activity [7, 29]. Furthermore, actin and the disruption of actin filaments influences epithelial Na\(^+\) channels [52]. Actin dynamics are mainly mediated by Rho-GTPases like Rac1, whose signaling pathway is also activated by RTKs and was shown to regulate ENaC in the kidney [30]. Additionally several studies have shown convergence of these pathways, where PI3-K promoted Rac1 signaling [53, 54]. Inhibition of AKT vigorously decreased ENaC activity in controls and MSCCM-treated FDLE cells. Akti 1/2-mediated AKT inhibition completely abolished the effect of MSC-CM. Although, Akti 1/2 also significantly reduced \(\Delta I_{amil}\) in controls, this effect was not seen for \(\Delta V_{amil}\) and \(\Delta V_{amil}\) confirms the prevention of MSC-CM efficacy by Akti 1/2. In contrast to AKT, no effect of the PI3-K inhibitor was seen on \(\Delta I_{amil}\) in control and MSC-CM-treated cells. On the other hand, \(\Delta V_{amil}\) and \(R_{te}\) of MSC-CM-treated FDLE cells was decreased by PI3-K inhibition. The increase of Na\(^+\) transport induced by MSC-CM in the presence of PI3-K inhibition was not evident for \(\Delta V_{amil}\). In this case, the reduced \(R_{te}\) erroneously lowered the calculated \(\Delta I_{amil}\), making the results of \(\Delta V_{amil}\) more reliable, which suggest that MSC-CM at least partly induced Na\(^+\) transport via PI3-K signaling. Notably, inhibition of Rac1 decreased Na\(^+\) transport in MSC-CM-treated FDLE cells that was not seen in controls. Although MSC-CM was still able to stimulate \(\Delta I_{amil}\) in the presence of the Rac1 inhibitor, this effect was not seen for \(\Delta V_{amil}\). Here, MSC-CM was not able to increase \(\Delta V_{amil}\) after Rac1 inhibition, suggesting that Rac1 signaling contributes at least in part to the stimulating effect of MSC-CM on Na\(^+\) transport. Regarding the results obtained in our study, we propose that yet unknown growth factors secreted by MSCs activate PI3-K and/or Rac1 signaling which leads to an increased ENaC activity. Furthermore, activated PI3K can stimulate Rac1, as shown previously [54]. However, the exact mechanisms, secreted factors and activated pathways responsible for stimulation of functional and structural lung maturation have to be determined in future studies.

**Conclusion**

In conclusion, within this study we were able to show that MSCs and their secreted factors in MSC-CM stimulate functional lung maturation by enhancing Na\(^+\) transport and surfactant protein mRNA expression in FDLE cells. We were also able to show that MSC-CM stimulated structural maturation of fetal lungs. In contrast to most studies, these results were obtained without any damaging insult like hyperoxia or LPS. Therefore, the study proposes a stimulation of maturation in fetal lungs by MSCs
instead of their repair capacity shown by others. These results thus suggest that MSCs may exert beneficial therapeutic effects on immature lungs of preterm infants prior to the onset of secondary or chronic lung diseases, which may represent a strategy to enhance the arrested lung development.

**Abbreviations**

AFC: alveolar fluid clearance
AKT: proteinkinase B
ALI: acute lung injury
amil\textsubscript{max}: maximal ENaC activity
ATII: alveolar type II
ARDS: acute respiratory distress syndrome
BM: bone marrow
BMP: bone morphogenetic protein
BMP-R: bone morphogenetic protein receptor
BPD: bronchopulmonary dysplasia
BSA: Bovine serum albumin
CM: conditioned medium
DAPI: 4',6-diamidino-2-phenylindole
DMEM: Dulbecco's modified Eagle's medium
ED: embryonic day
EGF: epidermal growth factor
EGF-R: epidermal growth factor receptor
ENaC: epithelial Na\textsuperscript{+} channel
EpCAM: epithelial cell adhesion molecule
FDLE: fetal distal lung epithelial
FGF: fibroblast growth factor
FGF-R: fibroblast growth factor receptor
FITC: Fluorescein isothiocyanate
HE: hematoxylin and eosin
HGF: hepatocyte growth factor
HGF-R: hepatocyte growth factor receptor (c-met)
$I_{\text{base}}$: basal current
$I_{\text{SC}}$: short-circuit current
LPS: lipopolysaccharide
Mrps18a: mitochondrial 28S ribosomal protein S18a
MSC: mesenchymal stem/stroma cell
MSC-CM: mesenchymal stem cell conditioned medium
MEM: minimum essential media
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NMDG: N-methyl-D-glucamine
$ouab_{\text{max}}$: maximal Na,K-ATPase activity
PBS: phosphate-buffered saline
PDGF: platelet derived growth factor
PDGF-R: platelet derived growth factor receptor
PI3-K: phosphoinositide 3-kinase
qPCR: real time quantitative PCR
Rac1: Ras-related C3 botulinum toxin substrate 1
RDS: respiratory distress syndrome
$R_{\text{te}}$: transepithelial resistance
RTK: receptor tyrosine kinase
TGF-β: transforming growth factor beta
TGF-β-R: transforming growth factor beta receptor
UC: umbilical cord
VEGF: vascular endothelial growth factor
VEGF-R: vascular endothelial growth factor receptor
$V_{te}$: transepithelial potential
$\Delta I_{amil}$: amiloride-sensitive $\Delta I_{SC}$
$\Delta V_{amil}$: amiloride-sensitive $\Delta V_{te}$

**Declarations**

**Ethics approval and consent to participate:**

The study was approved by the ethical board of the medical faculty of Leipzig University. Umbilical cord tissue was collected with informed consent of mothers.

**Consent for publication:**

Not applicable

**Availability of data and materials:**

All data generated or analyzed during this study are either included in this published article [and its supplementary information files], or can be obtained from the corresponding author on reasonable request.

**Competing interests:**

The authors declare that they have no competing interests.

**Funding:**

This research received no external funding.
Authors’ contribution:

JO: manuscript writing, collection and assembly of data, data analysis and interpretation; CF: conception and design, data analysis and interpretation, final approval of manuscript; UHT: provision of study material, final approval of manuscript; ML: conception and design, manuscript writing, data analysis and interpretation, provision of study material, final approval of manuscript

Acknowledgments:

We wish to thank Dr. Anja Bogen, Jessica Loeffler and Soeren Pietsch for excellent technical assistance. We acknowledge support from the Medical Faculty of Leipzig University, as well as support from Leipzig University for Open Access Publishing.

References

1. Bland RD. Lung Fluid Balance During Development. NeoReviews. 2005;6:e255–67. doi:10.1542/neo.6-6-e255.
2. Brodovich H, Hannam V, Seear M, Mullen JB. Amiloride impairs lung water clearance in newborn guinea pigs. J Appl Physiol. 1990;68:1758–62.
3. Fronius M, Clauss WG, Althaus M. Why Do We have to Move Fluid to be Able to Breathe? Front Physiol. 2012;3:146. doi:10.3389/fphys.2012.00146.
4. Schmidt C, Klammt J, Thome UH, Laube M. The interaction of glucocorticoids and progesterone distinctively affects epithelial sodium transport. Lung. 2014;192:935–46. doi:10.1007/s00408-014-9640-3.
5. Falin RA, Cotton CU. Acute downregulation of ENaC by EGF involves the PY motif and putative ERK phosphorylation site. J Gen Physiol. 2007;130:313–28. doi:10.1085/jgp.200709775.
6. Peters DM, Vadász I, Wujak L, Wygrecka M, Olschewski A, Becker C, et al. TGF-β directs trafficking of the epithelial sodium channel ENaC which has implications for ion and fluid transport in acute lung injury. Proc Natl Acad Sci U S A. 2014;111:E374-83. doi:10.1073/pnas.1306798111.
7. Deng W, Li C-Y, Tong J, Zhang W, Wang D-X. Regulation of ENaC-mediated alveolar fluid clearance by insulin via PI3K/Akt pathway in LPS-induced acute lung injury. Respir Res. 2012;13:29. doi:10.1186/1465-9921-13-29.
8. Bhalla V, Oyster NM, Fitch AC, Wijngaarden MA, Neumann D, Schlattner U, et al. AMP-activated Kinase Inhibits the Epithelial Na + Channel through Functional Regulation of the Ubiquitin Ligase Nedd4-2. J Biol Chem. 2006;281:26159–69. doi:10.1074/jbc.M606045200.
9. Walsh BK, Daigle B, DiBlasi RM, Restrepo RD. AARC Clinical Practice Guideline. Surfactant replacement therapy: 2013. Respir Care. 2013;58:367–75. doi:10.4187/respcare.02189.
10. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276:357–68. doi:10.1056/NEJM196702162760701.

11. Laube M, Stolzing A, Thome UH, Fabian C. Therapeutic potential of mesenchymal stem cells for pulmonary complications associated with preterm birth. Int J Biochem Cell Biol. 2016;74:18–32. doi:10.1016/j.biocel.2016.02.023.

12. O'Reilly M, Sozo F, Harding R. Impact of preterm birth and bronchopulmonary dysplasia on the developing lung: long-term consequences for respiratory health. Clin Exp Pharmacol Physiol. 2013;40:765–73. doi:10.1111/1440-1681.12068.

13. Jobe AJ. The New BPD: An Arrest of Lung Development. Pediatr Res. 1999;46:641. doi:10.1203/00006450-199912000-00007.

14. Baveja R, Christou H. Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol. 2006;30:209–18. doi:10.1053/j.semperi.2006.05.008.

15. Lv F-J, Tuan RS, Cheung KMC, Leung VYL. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014;32:1408–19. doi:10.1002/stem.1681.

16. Ding D-C, Chang Y-H, Shyu W-C, Lin S-Z. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015;24:339–47. doi:10.3727/096368915X686841.

17. Leibel S, Post M. Endogenous and Exogenous Stem/Progenitor Cells in the Lung and Their Role in the Pathogenesis and Treatment of Pediatric Lung Disease. Front Pediatr. 2016;4:36. doi:10.3389/fped.2016.00036.

18. Samper E, Diez-Juan A, Montero JA, Sepúlveda P. Cardiac cell therapy: boosting mesenchymal stem cells effects. Stem Cell Rev Rep. 2013;9:266–80. doi:10.1007/s12015-012-9353-z.

19. Aslam M, Baveja R, Liang OD, Fernandez-Gonzalez A, Lee C, Mitsialis SA, Kourembanas S. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med. 2009;180:1122–30. doi:10.1164/rccm.200902-0242OC.

20. van Haaften T, Byrne R, Bonnet S, Rochefort GY, Akabutu J, Bouchentouf M, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med. 2009;180:1131–42. doi:10.1164/rccm.200902-0179OC.

21. Di Bernardo J, Maiden MM, Jiang G, Hershenson MB, Kunisaki SM. Paracrine regulation of fetal lung morphogenesis using human placenta-derived mesenchymal stromal cells. J Surg Res. 2014;190:255–63. doi:10.1016/j.jss.2014.04.013.

22. Leeman KT, Pessina P, Lee J-H, Kim CF. Mesenchymal Stem Cells Increase Alveolar Differentiation in Lung Progenitor Organoid Cultures. Sci Rep. 2019;9:6479. doi:10.1038/s41598-019-42819-1.

23. Jassal D, Han RNN, Caniggia I, Post M, Tanswell AK. Growth of distal fetal rat lung epithelial cells in a defined serum-free medium. In Vitro Cellular Developmental Biology - Animal. 1991;27:625. doi:10.1007/BF02631105.
24. Thome U, Chen L, Factor P, Dumasi V, Freeman B, Szajder J, Matalon S. Na,K-ATPase gene transfer mitigates an oxidant-induced decrease of active sodium transport in rat fetal ATII cells. Am J Respir Cell Mol Biol. 2001;24:245–52. doi:10.1165/ajrcmb.24.3.3994.

25. Thome UH, Davis IC, Nguyen SV, Shelton BJ, Matalon S. Modulation of sodium transport in fetal alveolar epithelial cells by oxygen and corticosterone. Am J Physiol Lung Cell Mol Physiol. 2003;284:L376-85. doi:10.1152/ajplung.00218.2002.

26. del Moral P-M, Warburton D. Explant Culture of Mouse Embryonic Whole Lung, Isolated Epithelium, or Mesenchyme Under Chemically Defined Conditions as a System to Evaluate the Molecular Mechanism of Branching Morphogenesis and Cellular Differentiation. In: Ward A, Tosh D, editors. Mouse cell culture: Methods and protocols. New York: Humana Pr; 2010. pp. 71–9. doi:10.1007/978-1-59745-019-5_5.

27. Nogueira-Silva C, Piairo P, Carvalho-Dias E, Veiga C, Moura RS, Correia-Pinto J. The Role of Glycoprotein 130 Family of Cytokines in Fetal Rat Lung Development. PLoS ONE. 2013;8:e67607. doi:10.1371/journal.pone.0067607.

28. Kaltofen T, Haase M, Thome UH, Laube M. Male Sex is Associated with a Reduced Alveolar Epithelial Sodium Transport. PLoS ONE. 2015;10:e0136178. doi:10.1371/journal.pone.0136178.

29. Di Qi, He J, Wang D, Deng W, Zhao Y, Ye Y, Feng L. 17β-estradiol suppresses lipopolysaccharide-induced acute lung injury through PI3K/Akt/SGK1 mediated up-regulation of epithelial sodium channel (ENaC) in vivo and in vitro. Respir Res. 2014;15:159. doi:10.1186/s12931-014-0159-1.

30. Karpushev AV, Levchenko V, Ilatovskaya DV, Pavlov TS, Staruschenko A. Novel role of Rac1/WAVE signaling mechanism in regulation of the epithelial Na + channel. Hypertension. 2011;57:996–1002. doi:10.1161/HYPERTENSIONAHA.110.157784.

31. Ahn SY, Chang YS, Kim SY, Sung DK, Kim ES, Rime SY, et al. Long-term (postnatal day 70) outcome and safety of intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells in neonatal hyperoxic lung injury. Yonsei Med J. 2013;54:416–24. doi:10.3349/ymj.2013.54.2.416.

32. Sutsko RP, Young KC, Ribeiro A, Torres E, Rodriguez M, Hehre D, et al. Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury. Pediatr Res. 2013;73:46–53. doi:10.1038/pr.2012.152.

33. Hansmann G, Fernandez-Gonzalez A, Aslam M, Vitali SH, Martin T, Mitsialis SA, Kourembanas S. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ. 2012;2:170–81. doi:10.4103/2045-8932.97603.

34. Bonikos DS, Bensch KG, Northway WH Jr. Oxygen toxicity in the newborn. The effect of chronic continuous 100 percent oxygen exposure on the lungs of newborn mice. Am J Pathol. 1976;85:623–50.

35. O’Reilly M, Thébaud B. Animal models of bronchopulmonary dysplasia. The term rat models. American Journal of Physiology-Lung Cellular Molecular Physiology. 2014;307:L948–58. doi:10.1152/ajplung.00160.2014.
36. Matalon S, O’Brodovich H. SODIUM CHANNELS IN, ALVEOLAR EPITHELIAL CELLS. Molecular Characterization, Biophysical Properties, and Physiological Significance. Annu Rev Physiol. 1999;61:627–61. doi:10.1146/annurev.physiol.61.1.627.

37. Hummler E, Barker P, Gatzy J, Beermann F, Verdumo C, Schmidt A, et al. Early death due to defective neonatal lung liquid clearance in alpha-ENaC-deficient mice. Nat Genet. 1996;12:325–8. doi:10.1038/ng0396-325.

38. Barker PM, Gowen CW, Lawson EE, Knowles MR. Decreased sodium ion absorption across nasal epithelium of very premature infants with respiratory distress syndrome. J Pediatr. 1997;130:373–7. doi:10.1016/S0022-3476(97)70198-7.

39. Helve O, Pitkänen OM, Andersson S, O’Brodovich H, Kirjavainen T, Otulakowski G. Low expression of human epithelial sodium channel in airway epithelium of preterm infants with respiratory distress. Pediatrics. 2004;113:1267–72. doi:10.1542/peds.113.5.1267.

40. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163:1376–83. doi:10.1164/ajrccm.163.6.2004035.

41. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13. doi:10.1016/S0140-6736(20)30211-7.

42. Li J-W, Wu X. Mesenchymal stem cells ameliorate LPS-induced acute lung injury through KGF promoting alveolar fluid clearance of alveolar type II cells. Eur Rev Med Pharmacol Sci. 2015;19:2368–78.

43. Goolaerts A, Pellan-Randrianarison N, Larghero J, Vanneaux V, Uzunhan Y, Gille T, et al. Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury. Am J Physiol Lung Cell Mol Physiol. 2014;306:L975-85. doi:10.1152/ajplung.00242.2013.

44. McAuley DF, Curley GF, Hamid UI, Laffey JG, Abbott J, McKenna DH, et al. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. American Journal of Physiology-Lung Cellular Molecular Physiology. 2014;306:L809–15. doi:10.1152/ajplung.00358.2013.

45. Gennai S, Monsel A, Hao Q, Park J, Matthay MA, Lee JW. Microvesicles Derived From Human Mesenchymal Stem Cells Restore Alveolar Fluid Clearance in Human Lungs Rejected for Transplantation. Am J Transplant. 2015;15:2404–12. doi:10.1111/ajt.13271.

46. Wang L, Shi M, Tong L, Wang J, Ji S, Bi J, et al. Lung-Resident Mesenchymal Stem Cells Promote Repair of LPS-Induced Acute Lung Injury via Regulating the Balance of Regulatory T cells and Th17 cells. Inflammation. 2019;42:199–210. doi:10.1007/s10753-018-0884-6.

47. Knoll A, Brockmeyer T, Chevalier R, Zsheppang K, Nielsen H, Dammann C. Adult Rat Bone Marrow-Derived Stem Cells Promote Late Fetal Type II Cell Differentiation in a Co-Culture Model. Open Respir Med J. 2013;7:46–53. doi:10.2174/1874306401307010046.
48. Chen J, Li Y, Hao H, Li C, Du Y, Hu Y, et al. Mesenchymal Stem Cell Conditioned Medium Promotes Proliferation and Migration of Alveolar Epithelial Cells under Septic Conditions In Vitro via the JNK-P38 Signaling Pathway. Cell Physiol Biochem. 2015;37:1830–46. doi:10.1159/000438545.

49. Ilatovskaya DV, Pavlov TS, Levchenko V, Staruschenko A. ROS production as a common mechanism of ENaC regulation by EGF, insulin, and IGF-1. Am J Physiol Cell Physiol. 2013;304:C102–11. doi:10.1152/ajpcell.00231.2012.

50. Zheleznova NN, Wilson PD, Staruschenko A. Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells. Biochim Biophys Acta. 2011;1812:1301–13. doi:10.1016/j.bbadis.2010.10.004.

51. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62:65–74. doi:10.1124/mol.62.1.65.

52. Cantiello HF, Stow JL, Prat AG, Ausiello DA. Actin laments regulate epithelial Na + channel activity. American Journal of Physiology-Cell Physiology. 1991;261:C882–8. doi:10.1152/ajpcell.1991.261.5.C882.

53. Campa CC, Ciraolo E, Ghigo A, Germena G, Hirsch E. Crossroads of PI3K and Rac pathways. Small GTPases. 2015;6:71–80. doi:10.4161/21541248.2014.989789.

54. Welch HCE, Coadwell WJ, Stephens LR, Hawkins PT. Phosphoinositide 3-kinase-dependent activation of Rac. FEBS Lett. 2003;546:93–7. doi:10.1016/S0014-5793(03)00454-X.

55. Weaver M, Dunn NR, Hogan BL. Bmp4 and Fgf10 play opposing roles during lung bud morphogenesis. Development. 2000;127:2695–704.

56. Mailleux AA, Kelly R, Veltmaat JM, Langhe SP de, Zaffran S, Thiery JP, Belluscì S. Fgf10 expression identifies parabronchial smooth muscle cell progenitors and is required for their entry into the smooth muscle cell lineage. Development. 2005;132:2157–66. doi:10.1242/dev.01795.

57. Lee I-H, Song S-H, Cook DI, Dinudom A. H-Ras mediates the inhibitory effect of epidermal growth factor on the epithelial Na + channel. PLoS ONE. 2015;10:e0116938. doi:10.1371/journal.pone.0116938.

58. Catterton WZ, Escobedo MB, Sexson WR, Gray ME, Sundell HW, Stahlman MT. Effect of epidermal growth factor on lung maturation in fetal rabbits. Pediatr Res. 1979;13:104–8. doi:10.1203/00006450-197902000-00004.

59. Päivi J, Miettinen D, Warburton D, Bu J-S, Zhao JE, Berger P, Minoo, et al. Impaired Lung Branching Morphogenesis in the Absence of Functional EGF Receptor. Dev Biol. 1997;186:224–36. doi:10.1006/dbio.1997.8593.

60. Yoshimura S, Masuzaki H, Miura K, Gotoh H, Moriyama S, Fujishita A, Ishimaru T. Effect of epidermal growth factor on lung growth in experimental fetal pulmonary hypoplasia. Early Hum Dev. 2000;57:61–9. doi:10.1016/s0378-3782(99)00052-3.

61. Ramasamy SK, Mailleux AA, Gupte VV, Mata F, Sala FG, Veltmaat JM, et al. Fgf10 dosage is critical for the amplification of epithelial cell progenitors and for the formation of multiple mesenchymal
lineages during lung development. Dev Biol. 2007;307:237–47. doi:10.1016/j.ydbio.2007.04.033.

62. Chao C-M, Yahya F, Moiseenko A, Tiozzo C, Shrestha A, Ahmadvand N, et al. Fgf10 deficiency is causative for lethality in a mouse model of bronchopulmonary dysplasia. J Pathol. 2017;241:91–103. doi:10.1002/path.4834.

63. Upadhyay D, Lecuona E, Comellas A, Kamp DW, Sznajder JI. Fibroblast growth factor-10 upregulates Na,K-ATPase via the MAPK pathway. FEBS Lett. 2003;545:173–6. doi:10.1016/S0014-5793(03)00527-1.

64. Hiroaki Yamamoto EJ, Yun H-P, Gerber N, Ferrara JA, Whitsett, Thiennu H, Vu. Epithelial–vascular cross talk mediated by VEGF-A and 5HGF6 signaling directs primary septae formation during distal lung morphogenesis. Dev Biol. 2007;308:44–53. doi:10.1016/j.ydbio.2007.04.042.

65. Shen B-Q, Widdicombe JH, Mrsny RJ. Hepatocyte Growth Factor Inhibits Amiloride-Sensitive Na + Channel Function in Cystic Fibrosis Airway Epithelium in vitro. Pulm Pharmacol Ther. 1999;12:157–64. doi:10.1006/pupt.1999.9999.

66. SATO N, TAKAHASHI H. Hepatocyte growth factor promotes growth and lumen formation of fetal lung epithelial cells in primary culture. Respirilogy. 1997;2:185–91. doi:10.1111/j.1440-1843.1997.tb00077.x.

67. Matos AM, Gomes-Duarte A, Faria M, Barros P, Jordan P, Amaral MD, Matos P. Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR. Sci Rep. 2018;8:13026. doi:10.1038/s41598-018-31514-2.

68. Chelly N, Mouhieddine-Gueddiche OB, Barlier-Mur AM, Chailley-Heu B, Bourbon JR. Keratinocyte growth factor enhances maturation of fetal rat lung type II cells. Am J Respir Cell Mol Biol. 1999;20:423–32. doi:10.1165/ajrcmb.20.3.3201.

69. Yano T, Mason RJ, Pan T, Deterding RR, Nielsen LD, Shannon JM. KGF regulates pulmonary epithelial proliferation and surfactant protein gene expression in adult rat lung. American Journal of Physiology - Lung Cellular Molecular Physiology. 2000;279:L1146–58.

70. Borok Z, Mihyu S, Fernandes VF, Zhang XL, Kim KJ, Lubman RL. KGF prevents hyperoxia-induced reduction of active ion transport in alveolar epithelial cells. Am J Physiol. 1999;276:C1352-60. doi:10.1152/ajpcell.1999.276.6.C1352.

71. Hans Boström K, Willetts M, Pekny P, Levéen P, Lindahl H, Hedstrand, et al. PDGF-A Signaling Is a Critical Event in Lung Alveolar Myofibroblast Development and Alveogenesis. Cell. 1996;85:863–73. doi:10.1016/S0092-8674(00)81270-2.

72. Li J, Hoyle GW. Overexpression of PDGF-A in the Lung Epithelium of Transgenic Mice Produces a Lethal Phenotype Associated with Hyperplasia of Mesenchymal Cells. Dev Biol. 2001;239:338–49. doi:10.1006/dbio.2001.0441.

73. Serra R, Pelton RW, Moses HL. TGF beta 1 inhibits branching morphogenesis and N-myc expression in lung bud organ cultures. Development. 1994;120:2153–61.

74. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 2005;6:56. doi:10.1186/1465-9921-6-56.
75. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 2002;8:702–10. doi:10.1038/nm721.

76. Thébaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, Eaton F, et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation. 2005;112:2477–86. doi:10.1161/CIRCULATIONAHA.105.541524.

77. Brown KR, England KM, Goss KL, Snyder JM, Acarregui MJ. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1001-10. doi:10.1152/ajplung.2001.281.4.L1001.

78. McGillick EV, Orgeig S, Morrison JL. Structural and molecular regulation of lung maturation by intratracheal vascular endothelial growth factor administration in the normally grown and placentally restricted fetus. J Physiol (Lond). 2016;594:1399–420. doi:10.1113/JP271113.

Figures

Figure 1
MSC-CM increased activity and mRNA expression of Na+ transporters in FDLE cells. FDLE cells were subjected to MSC-CM or control medium for 24 h. Statistical differences between two groups were analyzed with a t-test. (A-C) Data are displayed as box and whiskers with the 10–90 percentile, mean (+) and median (horizontal line). (A) MSC-CM significantly enhanced Ibase and ∆lamil in FDLE cells (n = 78–82; ***p<0.001). (B) Maximal ENaC activity (amilmax) was significantly higher in FDLE cells cultured in MSC-CM (n = 26–27; **p<0.01). (C) Maximal Na,K-ATPase activity (ouabmax) was higher in FDLE cells treated with MSC-CM (n = 42–46; ***p<0.001). (D/E) Data are displayed as mean ± SEM. (D) mRNA expression of ENaC subunits (ENaCα, ENaCβ, ENaCγ) and Na,K ATPase subunits (Na,K ATPase α1 & Na,K ATPase β1) was increased by MSC-CM (n = 6–8; *p<0.05; **p<0.01; ***p<0.001). (E) Surfactant protein A1, B, C (Sftpa1, Sftpb, Sftpc) mRNA levels were elevated by MSC-CM (n = 3; *p<0.05; ***p<0.001). (□) control, (■) MSC-CM.

Figure 2
MSC-CM enhanced structural maturation and growth of fetal lung explants. Embryonic day 15 (ED15) fetal lung explants were subjected to MSC-CM or control medium for 4 days. Data are displayed as mean + SEM. Statistical differences between two groups were analyzed with a t-test. (A/B) Fetal lung explants cultured in MSC-CM were larger compared to controls (n = 9; *p<0.05; ***p<0.001; scale bar: 500 µm). (C) The ratio of tissue area to total area was similar in control and MSC-CM-treated lungs (n = 9). (D/E) MSC-CM increased the number of peripheral airway buds in lung explants (n = 3; *p<0.05; scale bar: 500 µm). (F) EpCAM (green) and DAPI (blue, nuclei) staining of lungs explants treated with control medium or MSC-CM (scale bar: 100 µm). (□) control, (■) MSC-CM.

Figure 3

Epithelial integrity and metabolic activity of FDLE cells was not affected by MSC-CM. FDLE cells were subjected to MSC-CM or control medium for 24 h. Data are displayed as mean + SEM or box and whiskers with the 10 90 percentile, mean (+) and median (horizontal line). Statistical differences between two groups were analyzed with a t-test. (A) Epithelial integrity was determined with FITC-dextran assays. MSC-CM had no effect on permeability of FDLE monolayers (n = 8). (B) Rte was not altered by MSC CM, determined in Ussing chambers (n = 28-31). (C) No altered metabolic activity was observed in MSC-CM-treated FDLE cells by MTT assays (n = 6). (□) control, (■) MSC-CM.
Growth factors were not responsible for the stimulating effect of MSC-CM on Na+ transport. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the respective growth receptor inhibitor. Data are displayed as box and whiskers with the 10 90 percentile, mean (+) and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey’s post hoc test. (A) Inhibition of VEGF-R with Axitinib (n = 19 24; ***p<0.001), (B) BMP-R with K02288 (n = 19 24; ***p<0.001) and (C) PDGF-R with AG-1296 (n = 19 24; ***p<0.001) did not affect Na+ transport in MSC-CM-treated and control cells. (D) The EGF-R inhibitor AG-1478 (n = 19 24; ***p<0.001), (E) the TGF-β-R inhibitor SB431542 (n = 19 24; *p<0.05; ***p<0.001), (F) the FGF-R inhibitor FIIN-2 (n = 19 24; *p<0.05; **p<0.01; ***p<0.001) and (G) the HGF-R (c-met) inhibitor PHA665752 (n = 64 67; **p<0.01; ***p<0.001) reduced ∆Iamil in control and MSC-CM-treated cells. Inhibition did not prevent the stimulating effect of MSC-CM. (□) control, (■) MSC-CM.
Inhibition of kinase signaling decreased MSC-CM-mediated Na+ channel activity. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the respective kinase inhibitor. Data are displayed as box and whiskers with the 10 90 percentile, mean (+) and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey’s post hoc test. (A) $\Delta I_{\text{amil}}$ was significantly reduced in both, MSC-CM-treated and control FDLE cells, when Akti 1/2 was present in the culture medium. MSC-CM was not able to increase $\Delta I_{\text{amil}}$ anymore ($n = 17$ 19; ***p<0.001). (B) Akti 1/2 did not affect Rte of FDLE cells. (C) $\Delta V_{\text{amil}}$ of both, control and MSC-CM-treated cells was decreased by Akti 1/2. AKT inhibition further prevented the increase of $\Delta V_{\text{amil}}$ induced by MSC-CM (***p<0.001). (D) LY294002-mediated inhibition of PI3-K did not affect $\Delta I_{\text{amil}}$ in MSC-CM-treated FDLE cells ($n = 42$ 50; ***p<0.001). (E) LY294002 significantly decreased Rte of FDLE cells cultured in MSC-CM (**p<0.01). (F) $\Delta V_{\text{amil}}$ of MSC-CM-treated cells was decreased by LY294002, which further prevented the MSC-CM-induced increase of $\Delta V_{\text{amil}}$ (***p<0.001). (□) control, (■) MSC-CM.
Figure 6

Inhibition of Rac1 impaired the effect of MSC-CM on Na+ transport. FDLE cells were subjected to MSC-CM or control medium for 24 h with or without the Rac1 inhibitor. Data are displayed as box and whiskers with the 10 90 percentile, mean (+) and median (horizontal line). Statistical differences among groups were analyzed with an ANOVA and Tukey's post hoc test. (A) ΔIamil was significantly reduced by Ehop 016 in FDLE cells cultured in MSC-CM. Controls were not affected by Rac1 inhibition (n = 38-44; ***p<0.001). (B) Rte of FDLE cells in MSC-CM was decreased by Ehop-016 (*p<0.05). (C) ΔVamil was decreased by Ehop 016 in MSC-CM-treated cells, which prevented the MSC-CM-induced increase of ΔVamil (***p<0.001). (□) control, (■) MSC-CM.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- FigureS3.pdf
- FigureS2.pdf
- FigureS1.pdf
- Supplements.docx